Haleon Group - HLN Total Debt to Capital

Haleon Group - graphic logo of issuer HLN

Haleon plc is a leading global player in the FMCG pharma segment with a global reach across the OTC market. The debt-to-equity ratio visualizes financial stability, while 0.47 reflects the baseline level of the metric. E-commerce growth and expansion in Asia support stable demand. A monopolistic focus on vitamins and hygiene guarantees predictable cash flows and strong margins.

Haleon (HLN): All Debt to Shareholders' Equity Ratio from 04/28/2023 to 10/31/2026
Finished products of haleon.com

Outsourcing production and distribution allows Haleon plc to optimize capital expenditures. The total debt-to-equity ratio measures the proportion of borrowed funds relative to equity, determining financial stability. A high value signals risks during rate hikes, while a low value indicates conservative growth. It is critical for investors to monitor the balance between leverage and liquidity. By analyzing changes in the business's leverage ratio, one can assess the issuer's current debt load.

Competitors of Haleon plc

KVUE (Kenvue) - Total Debt to Capital|VRNA: All Debt to Shareholders' Equity Ratio|Total Debt to Capital MENS|Total Debt to Capital Ligand Corp (LGND)|Debt to Equity Amneal Pharmaceuticals AMRX|All Debt to Shareholders' Equity Ratio PRGO|ALVO - Debt to Equity|Liquidia Corp (LQDA) - Total Debt to Equity Ratio|GLPG: Total Debt to Capital|ANI Pharmaceuticals Corp (ANIP) - Total Debt to Capital|Total Debt to Equity Ratio MNKD|AMPH: All Debt to Shareholders' Equity Ratio|Debt to Equity Pacira BioSciences, Inc. (PCRX)|SPRY - Debt to Capital|Theravance - Total Debt to Equity Ratio|Aggregate Debt to Capital AQST (Aquestive Corp)|scPharma - Total Debt to Capital|All Debt to Shareholders' Equity Ratio TECX (Tectonic Therapeutic, Inc.)|TNXP: Total Debt to Capital|Debt to Capital China SXT Pharmaceuticals, Inc. (SXTC)|Debt to Equity Eupraxia Pharmaceuticals, Inc.|BHST: All Debt to Shareholders' Equity Ratio|Total Debt to Capital EXOZ|ORMP (oramed.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital ENTX (Entera Bio)|Total Debt to Capital MindWalk Holdings, Inc. HYFT|ABVC - Debt to Equity|CPIX: Debt to Equity|QNTM: Total Debt to Capital|Debt to Capital fibrogen.com (FGEN)|Debt to Equity Telomir Pharmaceuticals, Inc.|Debt to Capital Rani Therapeutics Inc RANI|Debt to Equity Synergy CHC Corp (SNYR)|rallybio.com - Debt to Equity Ratio|Lexaria Bioscience Corp. - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio PULM|PTHL - Debt to Equity|Aggregate Debt to Equity APM|Lyra Therapeutics, Inc (LYRA) - Debt to Equity|IBO (Impact BioMedical, Inc.) - Debt to Equity|TNFA (TNF Pharmaceuticals Inc.) - Total Debt to Capital|Total Debt to Equity Ratio cbdMD Corp (YCBD)|Total Debt to Capital PRFX|CYTO (altamiratherapeutics.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Lipella LIPO|OptiNose Corp - Debt to Equity|PIRS - Debt to Equity|PROC (procapsgroup.com) - Debt to Equity Ratio|Petros Pharmaceuticals, Inc. (PTPI) - Debt to Equity|Aggregate Debt to Equity QLI (Qilian International Holding Group)|SLRN (ACELYRIN, Inc.) - Total Debt to Capital|TFFP: All Debt to Shareholders' Equity Ratio